Close Menu

NEW YORK (360Dx) – Ortho Clinical Diagnostics said today that it has received US Food and Drug Administration approval to market its Sera blood-grouping reagents with its ID-Micro Typing System gel card technology for extended phenotype testing.

Ortho's Sera reagents are used to determine the status of a designated antigen on human red blood cells. The firm noted that the reagents provide labs with a menu of antisera for phenotyping that's available in a gel testing format, and that covers more than 99 percent of the most commonly tested blood-group antigens.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.